Skip to content
Catalyst

folic acidWhat was measured

Measured, with no finding

6,833 endpoints

Show what was measuredHide what was measured
  • Bcl2/Bax and BclxL/Bax ratios in MCT cells after serum deprivation

    decreases, p = 0.05

    decreased Bcl2/Bax and BclxL/Bax ratios (P < 0.05)

    PMID 10720950 · one of two readings recorded this

  • renal Bcl2/Bax mRNA ratio

    decreases, p = 0.05

    Renal mRNA levels encoding for c-myc and BclxL were elevated in ARF while the Bcl2/Bax ratio was decreased (Bcl2 decreased and Bax increased; P < 0.05)

    PMID 10720950 · one of two readings recorded this

  • renal mRNA and protein levels of c-myc, Bcl2, Bax and BclxL (Northern blot, Western blot, immunohistochemistry) in murine kidneys after folic acid-induced ARF

    decreases, Bcl2/Bax ratio decreased

    Not recorded as a finding: this platform holds no node for the endpoint

    Renal mRNA levels encoding for c-myc and BclxL were elevated in ARF while the Bcl2/Bax ratio was decreased (Bcl2 decreased and Bax increased; P < 0.05).

    PMID 10720950 · one of two readings recorded this

  • sensitization to TNF-alpha-induced apoptosis in MCT cells

    increases, p = 0.05

    sensitization to TNF-alpha-induced apoptosis (P < 0.05)

    PMID 10720950 · one of two readings recorded this

  • sensitization to TNF-alpha-induced apoptosis with enforced BclxL overexpression

    decreases, p = 0.01

    The latter was prevented by enforced overexpression of BclxL (P < 0.01)

    PMID 10720950 · one of two readings recorded this

  • correlation of galectin-3 mRNA with serum reciprocal creatinine

    decreases, p = 0.0001, n = 13

    a significant negative correlation between galectin-3 mRNA expression and serum reciprocal creatinine was shown at 48 hours after injury (n = 13, r = -0.94, P: < 0.0001)

    PMID 10980121 · one of two readings recorded this

  • renal galectin-3 mRNA expression in folic acid-induced acute renal failure in rats

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    In folic acid-induced ARF, galectin-3 mRNA was found to be up-regulated at 2 hours after injury and increased levels continued until at least 7 days post-injury.

    PMID 10980121 · both readings recorded this

  • renal galectin-3 mRNA expression

    increases, p = 0.01

    galectin-3 mRNA began to increase at 2 hours and extended by 6.2-fold at 48 hours (P: < 0.01 versus normal control rats)

    PMID 10980121 · one of two readings recorded this

  • renal galectin-3 mRNA expression

    increases

    In folic acid-induced ARF, galectin-3 mRNA was found to be up-regulated at 2 hours after injury and increased levels continued until at least 7 days post-injury

    PMID 10980121 · one of two readings recorded this

  • renal galectin-3 mRNA expression

    decreases

    galectin-3 mRNA began to increase at 2 hours and extended by 6.2-fold at 48 hours (P: < 0.01 versus normal control rats), and then decreased by 28 days after injury

    PMID 10980121 · one of two readings recorded this

  • Ang-1 immunostaining in renal arterial walls and injured cortical tubules

    increases

    FA-induced nephropathy was associated with the acquisition of Ang-1 immunostaining in renal arterial walls and in a subset of injured cortical tubules

    PMID 11729241 · one of two readings recorded this

  • capillary proliferation (PCNA) near damaged tubules

    increases

    A subset of these endothelia expressed proliferating cell nuclear antigen, whereas capillary proliferation was absent in control samples

    PMID 11729241 · one of two readings recorded this

  • renal Ang-1 protein level (Western blot)

    increases

    Renal Ang-1 protein levels were significantly increased after FA administration, compared with time-matched control values, as assessed by Western blotting

    PMID 11729241 · one of two readings recorded this

  • renal angiopoietin-1 protein level by Western blotting after folic acid administration in mice

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Renal Ang-1 protein levels were significantly increased after FA administration, compared with time-matched control values, as assessed by Western blotting.

    PMID 11729241 · one of two readings recorded this

  • renal angiopoietin-1 protein level, Western blotting, in folic acid-induced nephrotoxicity in mice

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Renal Ang-1 protein levels were significantly increased after FA administration, compared with time-matched control values, as assessed by Western blotting.

    PMID 11729241 · one of two readings recorded this

  • tubular damage

    increases

    Tubular damage was detected 1 d after FA administration

    PMID 11729241 · one of two readings recorded this

  • tubular regeneration with patchy atrophy and interstitial fibrosis

    unclear

    in the next 14 d, most tubules regenerated but patchy atrophy, with interstitial fibrosis, was also observed

    PMID 11729241 · one of two readings recorded this

  • Birth length

    no effect

    Folic acid-iron and multiple micronutrients increased head and chest circumference of babies, but not length

    PMID 12637400 · one of two readings recorded this

  • birth size (birth weight, length, head and chest circumference) after maternal folic acid alone versus vitamin A alone control

    no effect, no effect on birth size

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Supplementation with maternal folic acid alone had no effect on birth size.

    PMID 12637400 · one of two readings recorded this

  • birth size (weight, length, head and chest circumference) after maternal folic acid alone vs vitamin A alone control

    no effect

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Supplementation with maternal folic acid alone had no effect on birth size.

    PMID 12637400 · one of two readings recorded this

  • Birth size

    no effect

    Supplementation with maternal folic acid alone had no effect on birth size

    PMID 12637400 · one of two readings recorded this

  • Birth size

    no effect

    Folic acid-iron-zinc had no effect on birth size compared with controls

    PMID 12637400 · one of two readings recorded this

  • Head and chest circumference

    increases

    Folic acid-iron and multiple micronutrients increased head and chest circumference of babies, but not length

    PMID 12637400 · one of two readings recorded this

  • Incidence of preterm births

    no effect

    None of the supplement combinations reduced the incidence of preterm births

    PMID 12637400 · one of two readings recorded this

  • Low birth weight (<2500 g)

    decreases

    reduced the percentage of low birthweight babies (<2500 g) from 43% to 34% (16%; relative risk=0.84, 0.72 to 0.99)

    PMID 12637400 · one of two readings recorded this

  • Low birth weight (<2500 g)

    decreases

    reduced the percentage of low birthweight babies by 14% (0.86, 0.74 to 0.99)

    PMID 12637400 · one of two readings recorded this

  • Mean birth weight

    increases

    Folic acid-iron increased mean birth weight by 37 g (95% confidence interval -16 g to 90 g)

    PMID 12637400 · one of two readings recorded this

  • Mean birth weight

    increases

    Multiple micronutrient supplementation increased birth weight by 64 g (12 g to 115 g)

    PMID 12637400 · one of two readings recorded this

  • ischaemic heart disease events

    decreases

    reduces IHD events by 88% (95% confidence interval 84% to 91%)

    PMID 12829553 · one of two readings recorded this

  • life years free from an IHD event or stroke gained, from age 55

    increases

    gaining on average about 11 years of life free from an IHD event or stroke

    PMID 12829553 · one of two readings recorded this

  • proportional reduction in ischaemic heart disease events and in stroke, estimated for a single daily pill (Polypill) from published meta-analyses

    decreases, IHD events reduced by 88% (95% CI 84% to 91%); stroke by 80% (71% to 87%)

    Not recorded as a finding: the intervention held more than the compound

    We estimate that the combination (which we call the Polypill) reduces IHD events by 88% (95% confidence interval 84% to 91%) and stroke by 80% (71% to 87%).

    PMID 12829553 · one of two readings recorded this

  • stroke

    decreases

    stroke by 80% (71% to 87%)

    PMID 12829553 · one of two readings recorded this

  • CpG methylation at the A(vy) locus in offspring

    increases

    dietary methyl supplementation of a/a dams with extra folic acid, vitamin B(12), choline, and betaine alter the phenotype of their A(vy)/a offspring via increased CpG methylation at the A(vy) locus

    PMID 12861015 · one of two readings recorded this

  • offspring phenotype and CpG methylation at the A(vy) locus in viable yellow agouti mice

    increases

    Not recorded as a finding: the intervention held more than the compound

    Our results show that dietary methyl supplementation of a/a dams with extra folic acid, vitamin B(12), choline, and betaine alter the phenotype of their A(vy)/a offspring via increased CpG methylation at the A(vy) locus

    PMID 12861015 · one of two readings recorded this

  • 6[R] 5-MTHF detected after folic acid administration (storage of isomer)

    unclear

    at 1 week after the administration of a single dosage 6[R,S] 5-MTHF, we detected 6[R] 5-MTHF following the administration of folic acid, indicating storage of this isomer in the body

    PMID 14769778 · one of two readings recorded this

  • Bioavailability (pharmacokinetic parameters)

    increases

    All pharmacokinetic parameters demonstrate that the bioavailability of 5-MTHF is higher compared to folic acid

    PMID 14769778 · one of two readings recorded this

  • Peak concentration of 6[S] and 6[R] 5-MTHF isomers

    increases

    The peak concentration of both isomers following the administration of 6[R,S] 5-MTHF is almost seven times higher compared to folic acid, irrespective of the patient's genotype

    PMID 14769778 · one of two readings recorded this

  • NTD recurrence, folic acid groups

    no effect, n = 261

    There was one NTD recurrence in the 89 infants/fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups

    PMID 1489222 · one of two readings recorded this

  • NTD recurrence, multivitamin group

    no effect, n = 261

    There was one NTD recurrence in the 89 infants/fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups

    PMID 1489222 · one of two readings recorded this

  • NTD recurrence, non-randomised control group

    unclear, n = 103

    there were three recurrences among the 103 infants in this group

    PMID 1489222 · one of two readings recorded this

  • recurrence of neural tube defects in infants/fetuses of women with a previously affected pregnancy

    no effect, one recurrence in 89 multivitamin infants/fetuses and none in 172 folic acid infants/fetuses, non-significant

    Not recorded as a finding: this platform holds no node for the endpoint

    There was one NTD recurrence in the 89 infants/fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups, a non-significant difference.

    PMID 1489222 · both readings recorded this

  • Bcl-2 protein expression in gastric mucosa

    decreases

    In contrast, the expression of Bcl-2 oncogene protein decreased after folic acid therapy

    PMID 15786529 · one of two readings recorded this

  • Epithelial apoptosis rate in gastric mucosa

    increases

    Both the epithelial apoptosis rate and the tumor suppressor p53 expression in gastric mucosa significantly increased after folic acid treatment

    PMID 15786529 · one of two readings recorded this

  • Folate concentration in gastric mucosa

    increases

    The mean of folate concentration in gastric mucosa was 9.03+/-3.37 microg/g wet wt in the folic acid treatment group, which was significantly higher than 6.83+/-3.02 microg/g wet wt in the control group

    PMID 15786529 · one of two readings recorded this

  • gastric epithelial apoptosis rate, Bcl-2 and p53 expression by flow cytometry, gastric mucosa folate concentration

    increases

    Not recorded as a finding: the comparison was against another active treatment

    Both the epithelial apoptosis rate and the tumor suppressor p53 expression in gastric mucosa significantly increased after folic acid treatment.

    PMID 15786529 · one of two readings recorded this

  • p53 protein expression in gastric mucosa

    increases

    Both the epithelial apoptosis rate and the tumor suppressor p53 expression in gastric mucosa significantly increased after folic acid treatment

    PMID 15786529 · one of two readings recorded this

  • Erythrocyte folate concentration

    increases, p = 0.001, n = 31

    and 57% (95% CI 40-74%; p<0.001 v placebo), respectively, and decreased plasma homocysteine concentration by 12% (95% CI 4-20%; p = 0.01 v placebo)

    PMID 15831910 · one of two readings recorded this

  • genomic DNA methylation in leucocytes and colonic mucosa; also serum and erythrocyte folate and plasma homocysteine

    increases, leucocyte DNA methylation +31% (95% CI 16-47%); colonic mucosa +25% (95% CI 11-39%), p = 0.05

    Not recorded as a finding: this platform holds no node for the endpoint

    Folic acid supplementation resulted in increases in DNA methylation of 31% (95% CI 16-47%; p = 0.05 v placebo) in leucocytes and 25% (95% CI 11-39%; p = 0.09 v placebo) in colonic mucosa.

    PMID 15831910 · one of two readings recorded this

  • genomic DNA methylation in leucocytes and colonic mucosa; serum and erythrocyte folate; plasma homocysteine

    increases, leucocyte DNA methylation +31% (95% CI 16-47%), colonic mucosa +25% (95% CI 11-39%)

    Not recorded as a finding: this platform holds no node for the endpoint

    Folic acid supplementation resulted in increases in DNA methylation of 31% (95% CI 16-47%; p = 0.05 v placebo) in leucocytes and 25% (95% CI 11-39%; p = 0.09 v placebo) in colonic mucosa.

    PMID 15831910 · one of two readings recorded this

  • Genomic DNA methylation

    increases, p = 0.09, n = 31

    25% (95% CI 11-39%; p = 0.09 v placebo) in colonic mucosa

    PMID 15831910 · one of two readings recorded this

  • Genomic DNA methylation

    increases, p = 0.05, n = 31

    increases in DNA methylation of 31% (95% CI 16-47%; p = 0.05 v placebo) in leucocytes

    PMID 15831910 · one of two readings recorded this

  • Plasma homocysteine concentration

    decreases, p = 0.01, n = 31

    decreased plasma homocysteine concentration by 12% (95% CI 4-20%; p = 0.01 v placebo)

    PMID 15831910 · one of two readings recorded this

  • Serum folate concentration

    increases, p = 0.001, n = 31

    Folic acid supplementation increased serum and erythrocyte folate concentrations by 81% (95% confidence interval (CI) 57-104%; p<0.001 v placebo)

    PMID 15831910 · one of two readings recorded this

  • Mean arterial pressure

    decreases, p = 0.03, n = 14

    Folate was associated with a reduction in mean arterial pressure (100 +/- 12 mm Hg vs. 96 +/- 11 mm Hg, placebo vs. folate, p < 0.03)

    PMID 15893170 · one of two readings recorded this

  • Dilator reserve (myocardial flow reserve)

    increases, p = 0.05, n = 14

    folate increased dilator reserve by 83% in abnormal segments (0.77 +/- 0.59 vs. ml/min/g 1.41 +/- 1.08 ml/min/g, placebo vs. folate, p < 0.05)

    PMID 15893170 · one of two readings recorded this

  • Dilator reserve (myocardial flow reserve)

    no effect, n = 14

    whereas dilator reserve in normal segments remained unchanged (2.00 +/- 0.61 ml/min/g vs. 2.12 +/- 0.69 ml/min/g, placebo vs. folate, p = NS)

    PMID 15893170 · one of two readings recorded this

  • MBF dose response to adenosine

    increases, p = 0.001, n = 14

    folic acid significantly increased the MBF dose response to adenosine (p < 0.001 using analysis of variance) in abnormal zones

    PMID 15893170 · one of two readings recorded this

  • MBF dose response to adenosine

    no effect, n = 14

    whereas MBF in normal zones did not change

    PMID 15893170 · one of two readings recorded this

  • myocardial blood flow and dilator reserve by positron emission tomography

    increases, peak MBF +49% in abnormal segments, 1.45 vs 2.16 ml/min/g

    Not recorded as a finding: no outcome node for myocardial blood flow or myocardial flow reserve by PET

    In abnormal segments, folic acid increased peak MBF by 49% (1.45 +/- 0.59 ml/min/g vs. 2.16 +/- 1.01 ml/min/g, p < 0.02).

    PMID 15893170 · one of two readings recorded this

  • peak myocardial blood flow after adenosine, positron emission tomography, abnormal myocardial zones only

    increases, peak MBF 1.45 vs 2.16 ml/min/g, +49%

    Not recorded as a finding: no outcome node for PET myocardial blood flow or myocardial flow reserve; result is for abnormal-zone subgroup

    In abnormal segments, folic acid increased peak MBF by 49% (1.45 +/- 0.59 ml/min/g vs. 2.16 +/- 1.01 ml/min/g, p < 0.02).

    PMID 15893170 · one of two readings recorded this

  • Peak myocardial blood flow

    increases, p = 0.02, n = 14

    In abnormal segments, folic acid increased peak MBF by 49% (1.45 +/- 0.59 ml/min/g vs. 2.16 +/- 1.01 ml/min/g, p < 0.02)

    PMID 15893170 · one of two readings recorded this

  • between-study heterogeneity of TT versus CC odds ratios

    unclear, p = 0.001

    There was strong evidence of heterogeneity (P < 0.001, I2 = 38.4%)

    PMID 16216822 · one of two readings recorded this

  • coronary heart disease (myocardial infarction or coronary artery occlusion), TT versus CC genotype

    increases

    An overall random effects odds ratio of 1.14 (95% confidence intervals 1.05 to 1.24) was found for TT versus CC genotype

    PMID 16216822 · one of two readings recorded this

  • all-cause mortality

    no effect

    relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively

    PMID 16413878 · one of two readings recorded this

  • all-cause mortality

    no effect

    relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively

    PMID 16413878 · one of two readings recorded this

  • all-cause mortality in children aged 1-36 months, intention to treat

    no effect, RR 1.03 (0.78-1.37) iron and folic acid; 1.00 (0.74-1.34) with zinc

    Not recorded as a finding: the intervention held more than the compound

    There was no difference in all-cause mortality by treatment group, with relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively (table 3).

    PMID 16413878 · one of two readings recorded this

  • all-cause mortality in children aged 1-36 months

    no effect, RR 1.03 (0.78-1.37) without zinc and 1.00 (0.74-1.34) with zinc

    Not recorded as a finding: the intervention held more than the compound

    There was no difference in all-cause mortality by treatment group, with relative risks (95% CIs) of 1·03 (0·78−1·37) and 1·00 (0·74−1·34) without and with zinc, respectively (table 3).

    PMID 16413878 · one of two readings recorded this

  • all-cause mortality, interaction with age

    no effect, p = 0.86

    test for interaction: iron and folic acid vs placebo p=0·86; iron and folic acid with zinc vs placebo p=0·85

    PMID 16413878 · one of two readings recorded this

  • all-cause mortality, interaction with age

    no effect, p = 0.85

    test for interaction: iron and folic acid vs placebo p=0·86; iron and folic acid with zinc vs placebo p=0·85

    PMID 16413878 · one of two readings recorded this

  • haemoglobin and serum ferritin concentrations

    increases

    concentrations of both haemoglobin and serum ferritin were significantly higher in the groups taking iron and folic acid than in the placebo group

    PMID 16413878 · one of two readings recorded this

  • incidence of acute lower respiratory illness

    no effect

    There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups

    PMID 16413878 · one of two readings recorded this

  • incidence of diarrhoea

    no effect

    There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups

    PMID 16413878 · one of two readings recorded this

  • incidence of dysentery

    no effect

    There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups

    PMID 16413878 · one of two readings recorded this

  • incidence of persistent diarrhoea

    no effect

    There were no significant differences in the incidence of diarrhoea, persistent diarrhoea, dysentery, or acute lower respiratory illness between the iron and folic acid and placebo groups

    PMID 16413878 · one of two readings recorded this

  • mortality from other infections

    increases

    Although the CIs for the point estimate of the relative risk of 3·58 (1·05−13·52) were above 1·00

    PMID 16413878 · one of two readings recorded this

  • overall anaemia rate

    decreases

    45% (37·7−53·4) and 48% (37·5, 56·2) in the groups taking iron and folic acid without and with zinc

    PMID 16413878 · one of two readings recorded this

  • overall anaemia rate

    decreases

    45% (37·7−53·4) and 48% (37·5, 56·2) in the groups taking iron and folic acid without and with zinc

    PMID 16413878 · one of two readings recorded this

  • overall anaemia rate

    Overall rates of anaemia were 62% (48·2−69·7) in the placebo group

    PMID 16413878 · one of two readings recorded this

  • prevalence of iron-deficiency anaemia, relative reduction vs placebo

    decreases

    The prevalence of iron-deficiency anaemia was 84% (65−92) lower in the group taking iron and folic acid

    PMID 16413878 · one of two readings recorded this

  • prevalence of iron-deficiency anaemia, relative reduction vs placebo

    decreases

    53% (18−73) lower in the group taking iron and folic acid with zinc than in the placebo group

    PMID 16413878 · one of two readings recorded this

  • severe anaemia prevalence

    decreases

    only 1% (0·1−4·6) of those in the iron and folic acid group

    PMID 16413878 · one of two readings recorded this

  • severe anaemia prevalence

    decreases

    3% (1·1−5·8) of those taking iron and folic acid with zinc were severely anaemic

    PMID 16413878 · one of two readings recorded this

  • severe anaemia prevalence

    6% (95% CI 2·6−10·7) of children in the placebo group had severe anaemia

    PMID 16413878 · one of two readings recorded this

  • proportion of total urinary arsenic excreted as DMA

    increases, p = 0.0001

    The increase in the proportion of total urinary arsenic excreted as DMA in the folic acid group (72% before and 79% after supplementation) was significantly (P < 0.0001) greater than that in the placebo group

    PMID 17093162 · one of two readings recorded this

  • proportion of total urinary arsenic excreted as InAs

    decreases, p = 0.001

    as InAs (15% and 11%, respectively; P < 0.001)

    PMID 17093162 · one of two readings recorded this

  • proportion of total urinary arsenic excreted as MMA

    decreases, p = 0.0001

    excreted as MMA (13% and 10%, respectively; P < 0.0001)

    PMID 17093162 · one of two readings recorded this

  • blood DMAs

    no effect

    There was no change in DMAs in blood

    PMID 17921403 · one of two readings recorded this

  • blood MMAs reduction

    decreases, p = 0.0001

    MMAs in blood was reduced by a mean +/- SE of 22.24 +/- 2.86% in the folic acid supplementation group and by 1.24 +/- 3.59% in the placebe group (P < 0.0001)

    PMID 17921403 · one of two readings recorded this

  • total blood arsenic and blood MMAs, DMAs, InAs concentrations; urinary DMAs

    decreases, total blood arsenic reduced 13.62% vs 2.49% on placebo, p = 0.0199

    Not recorded as a finding: this platform holds no node for the endpoint

    Total blood arsenic was reduced by 13.62% in the folic acid supplementation group and by 2.49% in the placebo group (P = 0.0199).

    PMID 17921403 · one of two readings recorded this

  • total blood arsenic reduction

    decreases, p = 0.0199

    Total blood arsenic was reduced by 13.62% in the folic acid supplementation group and by 2.49% in the placebo group (P = 0.0199)

    PMID 17921403 · one of two readings recorded this

  • urinary DMAs

    increases, p = 0.0099

    DMAs is rapidly excreted in urine as evidenced by an increase in urinary DMAs (P = 0.0099)

    PMID 17921403 · one of two readings recorded this

  • correlation of synthetic folate intake with plasma folate

    increases, p = 0.0001, n = 55

    Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.49 | < 0.0001

    PMID 17961229 · one of two readings recorded this

  • correlation of synthetic folate intake with plasma folate

    increases, p = 0.001, n = 53

    Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.49 | < 0.0001

    PMID 17961229 · one of two readings recorded this

  • correlation of synthetic folate intake with RBC folate

    increases, p = 0.01, n = 55

    RBC folate | 53 | 0.31 | < 0.05 | 55 | 0.36 | < 0.01

    PMID 17961229 · one of two readings recorded this

  • correlation of synthetic folate intake with RBC folate

    increases, p = 0.05, n = 53

    RBC folate | 53 | 0.31 | < 0.05 | 55 | 0.36 | < 0.01

    PMID 17961229 · one of two readings recorded this

  • correlation of total folate intake with plasma folate

    increases, p = 0.001, n = 55

    Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.46 | < 0.001

    PMID 17961229 · one of two readings recorded this

  • correlation of total folate intake with plasma folate

    increases, p = 0.001, n = 53

    Plasma folate | 53 | 0.47 | < 0.001 | 55 | 0.46 | < 0.001

    PMID 17961229 · one of two readings recorded this

  • correlation of total folate intake with RBC folate

    increases, p = 0.01, n = 55

    RBC folate | 53 | 0.32 | < 0.05 | 55 | 0.36 | <0.01

    PMID 17961229 · one of two readings recorded this

  • correlation of total folate intake with RBC folate

    increases, p = 0.05, n = 53

    RBC folate | 53 | 0.32 | < 0.05 | 55 | 0.36 | <0.01

    PMID 17961229 · one of two readings recorded this

  • dietary folate intake

    Dietary folate, μg/d | 225 (193, 322) | 253 (208, 320) | 271 (214, 331) | 268 (217, 326)

    PMID 17961229 · one of two readings recorded this

  • dietary folate intake

    Dietary folate, μg/d | 225 (193, 322) | 253 (208, 320) | 271 (214, 331) | 268 (217, 326)

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by plasma folate

    increases, p = 0.0001, n = 55

    Plasma folate | 55 | 47 | 33 | 20 | <0.0001

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by plasma folate

    no effect, p = 0.1427, n = 53

    Plasma folate | 53 | 28 | 44 | 28 | 0.1427

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by plasma folate

    unclear, p = 0.0001, n = 18

    Plasma folate | 18 | 6 | 50 | 44 | <0.0001

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by plasma folate

    no effect, p = 0.2707, n = 17

    Plasma folate | 17 | 18 | 41 | 41 | 0.2707

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by RBC folate

    increases, p = 0.05, n = 55

    RBC folate | 55 | 33 | 43 | 24 | < 0.05

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by RBC folate

    increases, p = 0.001, n = 53

    RBC folate | 53 | 40 | 40 | 20 | < 0.001

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by RBC folate

    no effect, p = 0.7866, n = 18

    RBC folate | 18 | 22 | 39 | 39 | 0.7866

    PMID 17961229 · one of two readings recorded this

  • percentage correctly classified into folate intake quartile by RBC folate

    no effect, p = 0.0588, n = 17

    RBC folate | 17 | 35 | 30 | 35 | 0.0588

    PMID 17961229 · one of two readings recorded this

  • plasma folate

    Plasma folate (nmol/L) | 59 (41, 85) | 46 (29, 63) | 110 (74, 143) | 93 (71, 120)

    PMID 17961229 · one of two readings recorded this

  • plasma folate

    Plasma folate (nmol/L) | 59 (41, 85) | 46 (29, 63) | 110 (74, 143) | 93 (71, 120)

    PMID 17961229 · one of two readings recorded this

  • plasma homocysteine

    Plasma homocysteine (μmol/L) | 8.8 (8.1, 9.6) | 8.7 (8.0, 9.4) | 9.2 (8.6, 9.8) | 8.9 (8.2, 9.6)

    PMID 17961229 · one of two readings recorded this

  • plasma homocysteine

    Plasma homocysteine (μmol/L) | 8.8 (8.1, 9.6) | 8.7 (8.0, 9.4) | 9.2 (8.6, 9.8) | 8.9 (8.2, 9.6)

    PMID 17961229 · one of two readings recorded this

  • prenatal folic acid from supplements

    The average amount of folic acid provided by the supplements prenatally was 923 ± 239 μg/d

    PMID 17961229 · one of two readings recorded this

  • proportion with RBC folate above 906 nmol/L

    % > 906 nmol/L2 | 100 | 89 | 100 | 100

    PMID 17961229 · one of two readings recorded this

  • proportion with RBC folate above 906 nmol/L

    % > 906 nmol/L2 | 100 | 89 | 100 | 100

    PMID 17961229 · one of two readings recorded this

  • RBC folate

    RBC folate (nmol/L) | 2190 (1875, 2626) | 1374 (1025, 1692) | 3024 (2313, 3992) | 2090 (1641, 2527)

    PMID 17961229 · one of two readings recorded this

  • RBC folate

    RBC folate (nmol/L) | 2190 (1875, 2626) | 1374 (1025, 1692) | 3024 (2313, 3992) | 2090 (1641, 2527)

    PMID 17961229 · one of two readings recorded this

  • synthetic folate intake

    Synthetic folate, μg/d3 | 147 (75, 174) | 118 (87, 151) | 472 (408, 511) | 450 (410, 479)

    PMID 17961229 · one of two readings recorded this

  • synthetic folate intake

    Synthetic folate, μg/d3 | 147 (75, 174) | 118 (87, 151) | 472 (408, 511) | 450 (410, 479)

    PMID 17961229 · one of two readings recorded this

  • total folate intake

    Total folate, μg DFE/d | 481 (400, 561) | 467 (379, 543) | 1072 (983, 1163) | 1040 (953, 1135)

    PMID 17961229 · one of two readings recorded this

  • total folate intake

    Total folate, μg DFE/d | 481 (400, 561) | 467 (379, 543) | 1072 (983, 1163) | 1040 (953, 1135)

    PMID 17961229 · one of two readings recorded this

  • composite of myocardial infarction, stroke, coronary revascularization, or CVD mortality

    no effect, RR 1.03, 95% CI 0.90-1.19, p = 0.65

    Not recorded as a finding: the intervention held more than the compound

    Patients receiving active vitamin treatment had similar risk for the composite CVD primary end point (226.9/10,000 person-years vs 219.2/10,000 person-years for the active vs placebo group; relative risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.19; P = .65), as well as for the secondary outcomes including myocardial infarction (34.5/10,000 person-years vs 39.5/10,000 person-years; RR, 0.87; 95% CI, 0.63-1.22; P = .42), stroke (41.9/10,000 person-years vs 36.8/10,000 person-years; RR, 1.14; 95% CI, 0.82-1.57; P = .44), and CVD mortality (50.3/10,000 person-years vs 49.6/10,000 person-years; RR, 1.01; 95% CI, 0.76-1.35; P = .93).

    PMID 18460663 · one of two readings recorded this

  • composite of myocardial infarction, stroke, coronary revascularization, or CVD mortality

    no effect, p = 0.65

    (226.9/10,000 person-years vs 219.2/10,000 person-years for the active vs placebo group; relative risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.19; P = .65)

    PMID 18460663 · one of two readings recorded this

  • confirmed CVD events (count)

    no effect, n = 796

    a total of 796 women experienced a confirmed CVD event (406 in the active group and 390 in the placebo group)

    PMID 18460663 · one of two readings recorded this

  • CVD mortality

    no effect, p = 0.93

    CVD mortality (50.3/10,000 person-years vs 49.6/10,000 person-years; RR, 1.01; 95% CI, 0.76-1.35; P = .93)

    PMID 18460663 · one of two readings recorded this

  • myocardial infarction

    no effect, p = 0.42

    myocardial infarction (34.5/10,000 person-years vs 39.5/10,000 person-years; RR, 0.87; 95% CI, 0.63-1.22; P = .42)

    PMID 18460663 · one of two readings recorded this

  • plasma homocysteine, difference vs placebo

    decreases

    for a difference of 2.27 micromol/L (95% CI, 1.54-2.96 micromol/L)

    PMID 18460663 · one of two readings recorded this

  • plasma homocysteine, geometric mean relative decrease

    decreases, p = 0.001, n = 300

    geometric mean plasma homocysteine level was decreased by 18.5% (95% CI, 12.5%-24.1%; P < .001) in the active group (n = 150) over that observed in the placebo group (n = 150)

    PMID 18460663 · one of two readings recorded this

  • stroke

    no effect, p = 0.44

    stroke (41.9/10,000 person-years vs 36.8/10,000 person-years; RR, 1.14; 95% CI, 0.82-1.57; P = .44)

    PMID 18460663 · one of two readings recorded this

  • peritubular capillary stability

    increases

    delivery of angiopoietin-1 by adenoviral vectors stabilized peritubular capillaries in folic acid nephropathy

    PMID 18480750 · one of two readings recorded this

  • profibrotic and inflammatory effects

    increases

    delivery of angiopoietin-1 by adenoviral vectors stabilized peritubular capillaries in folic acid nephropathy but this was accompanied by profibrotic and inflammatory effects

    PMID 18480750 · one of two readings recorded this

  • adenoma recurrence

    decreases

    Patients below 70 years of age and those with left-sided colonic adenomas or advanced adenomas responded better to folic acid supplementation

    PMID 18680228 · one of two readings recorded this

  • adenoma recurrence

    decreases

    Patients below 70 years of age and those with left-sided colonic adenomas or advanced adenomas responded better to folic acid supplementation

    PMID 18680228 · one of two readings recorded this

  • adenoma recurrence

    decreases

    Patients below 70 years of age and those with left-sided colonic adenomas or advanced adenomas responded better to folic acid supplementation

    PMID 18680228 · one of two readings recorded this

  • mean number of recurrent adenomas

    decreases, n = 94

    The mean number of recurrent polyps at 3-year was 0.36 (SD, 0.69) for folic acid treated patients compared to 0.82 (SD, 1.17) for placebo treated subjects

    PMID 18680228 · one of two readings recorded this

  • advanced lesion risk

    no effect

    showed a borderline non-significant inverse association with risk of all adenomas (RR for Q4 vs. Q1=0.83; 95% CI=0.64-1.08, Table 3), but not with advanced lesions (RR for Q4 vs. Q1=0.78; 95% CI=0.39-1.57, Table 3)

    PMID 18708408 · one of two readings recorded this

  • advanced lesion risk

    no effect

    did not show any association with risk of any adenoma (RR for Q4 vs. Q1=1.05; 95% CI=0.78-1.41) or advanced lesions (RR for Q4 vs. Q1=0.99; 95% CI=0.46-2.12, Table 3)

    PMID 18708408 · one of two readings recorded this

  • advanced lesion risk

    no effect

    we observed no association with any adenoma (RR for Q4 vs. Q1=1.02; 95%CI=0.85-1.23) or advanced lesions (RR for Q4 vs. Q1=1.07; 95% CI= 0.66-1.73)

    PMID 18708408 · one of two readings recorded this

  • advanced lesion risk

    no effect

    For advanced lesions, the PL RR for Q4 vs. Q1 was 0.65 (95% CI=0.32-1.32 in a fully adjusted model)

    PMID 18708408 · one of two readings recorded this

  • advanced lesion risk

    no effect

    there was no association between PLP levels and risk of advanced lesions (RR for Q4 vs. Q1=0.89, 95% CI=0.46-1.73)

    PMID 18708408 · one of two readings recorded this

  • advanced lesion risk

    no effect

    no significant association between baseline plasma B12 and risk of any adenoma (RR for Q4 vs. Q1=0.91, 95% CI=0.73-1.15) or advanced lesions (RR for Q4 vs. Q1=0.94, 95% CI=0.52-1.69, Table 2)

    PMID 18708408 · one of two readings recorded this

  • advanced lesion risk

    decreases, p = 0.12

    although there was a statistically significant inverse association for advanced lesions (RR for Q4 vs. Q1=0.51, 95% CI=0.26-0.99, p-trend=0.12, Table 2)

    PMID 18708408 · one of two readings recorded this

  • alcohol consumption, subjects with new adenomas vs without

    increases, p = 0.006

    but were more likely to have lower baseline plasma folate levels (p=0.025) and consume more alcohol (p=0.006)

    PMID 18708408 · one of two readings recorded this

  • any adenoma recurrence risk

    increases

    We observed a significantly increased risk for any adenoma recurrence among individuals with the CBS-1080 T/T genotype compared to those with at least one C allele (RR=1.29, 95% CI=1.06-1.56)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk with higher plasma vitamin B2

    no effect

    while those who were heterozygotes or homozygotes for the common 677C allele showed a reduced risk (adjusted RR=0.87; 95% CI=0.73-1.03, p-interaction=0.07)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk with higher plasma vitamin B2

    no effect

    Among subjects who were homozygotes for the (variant) T allele there was a non-significantly increased risk of adenomas associated with higher plasma vitamin B2 (adjusted RR=1.40; 95% CI=0.85-2.30)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    The relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66 G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it was 0.80 (95% CI=0.62-1.03)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    showed a borderline non-significant inverse association with risk of all adenomas (RR for Q4 vs. Q1=0.83; 95% CI=0.64-1.08, Table 3), but not with advanced lesions (RR for Q4 vs. Q1=0.78; 95% CI=0.39-1.57, Table 3)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    did not show any association with risk of any adenoma (RR for Q4 vs. Q1=1.05; 95% CI=0.78-1.41) or advanced lesions (RR for Q4 vs. Q1=0.99; 95% CI=0.46-2.12, Table 3)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    The relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66 G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it was 0.80 (95% CI=0.62-1.03)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    The relative risk for MTR-2756 A/G or G/G vs. A/A was 0.99 (95% CI=0.85-1.15), for MTRR-66 G/G vs. A/A or A/G it was 0.97 (95% CI=0.83-1.14) and for CBS-699 T/T vs. C/C or C/T it was 0.80 (95% CI=0.62-1.03)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    we observed no association with any adenoma (RR for Q4 vs. Q1=1.02; 95%CI=0.85-1.23) or advanced lesions (RR for Q4 vs. Q1=1.07; 95% CI= 0.66-1.73)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    decreases

    Baseline PL levels were also inversely associated with all adenoma risk (RR for Q4 vs. Q1=0.78; 95% CI=0.62-0.99)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    an association that was attenuated after further adjustment for plasma B2, B12 and folate (RR for Q4 vs. Q1=0.86; 95% CI=0.66-1.12)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect, p = 0.08

    Baseline PLP concentration was borderline inversely associated with risk of any adenoma (RR for Q4 vs. Q1=0.78, 95% CI=0.61-1.00, p-trend=0.08, Table 2)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    no significant association between baseline plasma B12 and risk of any adenoma (RR for Q4 vs. Q1=0.91, 95% CI=0.73-1.15) or advanced lesions (RR for Q4 vs. Q1=0.94, 95% CI=0.52-1.69, Table 2)

    PMID 18708408 · one of two readings recorded this

  • any adenoma risk

    no effect

    Baseline plasma vitamin B2 was not significantly associated with adenoma risk (adjusted RR for Q4 vs. Q1=0.95, 95% CI=0.75-1.20)

    PMID 18708408 · one of two readings recorded this

  • baseline plasma folate, subjects with new adenomas vs without

    decreases, p = 0.025

    but were more likely to have lower baseline plasma folate levels (p=0.025) and consume more alcohol (p=0.006)

    PMID 18708408 · one of two readings recorded this

  • correlation of dietary B2 intake with plasma B2

    increases, p = 0.001

    Baseline dietary vitamin B2 was modestly correlated with plasma levels (rho=0.1; p<0.001)

    PMID 18708408 · one of two readings recorded this

  • correlation of dietary B6 intake with plasma PL

    increases, p = 0.001

    Baseline dietary vitamin B6 intake was modestly correlated with plasma PLP and PL (rho=0.17 and 0.15, respectively; p<0.001)

    PMID 18708408 · one of two readings recorded this

  • correlation of dietary B6 intake with plasma PLP

    increases, p = 0.001

    Baseline dietary vitamin B6 intake was modestly correlated with plasma PLP and PL (rho=0.17 and 0.15, respectively; p<0.001)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma B12 with plasma folate

    increases

    Similarly, plasma B12 and folate were modestly correlated (rho=0.34)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma B2 with plasma B12

    increases

    Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma B2 with plasma folate

    increases

    Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma B2 with plasma PL

    increases

    Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma B2 with plasma PLP

    increases

    Plasma B2 was modestly correlated with PLP (rho=0.44), PL (rho=0.50), B12 (rho=0.30) and folate (rho=0.45)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma PL with plasma B12

    increases

    both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma PL with plasma folate

    increases

    both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma PLP with plasma B12

    increases

    both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma PLP with plasma folate

    increases

    both were modestly correlated with plasma vitamin B12 (rho=0.38 and 0.34, respectively) and folate (rho=0.48 and 0.53, respectively)

    PMID 18708408 · one of two readings recorded this

  • correlation of plasma PLP with plasma PL

    increases

    Plasma PLP and PL were strongly correlated (rho=0.82)

    PMID 18708408 · one of two readings recorded this

  • subjects with one or more colorectal adenoma at follow-up

    n = 1084

    Of the 1,084 subjects with endpoint data, 471 (43.5%) were found to have one or more colorectal adenoma at least one year after randomization

    PMID 18708408 · one of two readings recorded this

  • time from randomization to completion of first follow-up interval

    The mean (SD) time from randomization to completion of the first follow-up interval was 32.7 (3.6) months

    PMID 18708408 · one of two readings recorded this

  • augmentation index change during HD

    decreases, p = 0.013, n = 10

    By contrast, intra-HD F administration was associated with significant increases in F (+298 +/- 283 nmol l(-1), P = 0.010) and a significant reduction of AIx (-4.7 +/- 7.2%, P = 0.013), but no effects on salbutamol-mediated AIx changes (+1.5 +/- 4.4%)

    PMID 18754845 · one of two readings recorded this

  • augmentation index change during HD

    no effect, n = 10

    Pre-HD F administration did not prevent significant reductions in F during HD (end-HD vs. pre-HD, -865 +/- 465 nmol l(-1), P < 0.001), but no significant changes in AIx (+1.4 +/- 5.7%) or salbutamol-mediated AIx modifications (+0.4 +/- 5.5%) were observed

    PMID 18754845 · one of two readings recorded this

  • HD-induced reduction in plasma ADMA

    unclear, p = 0.066, n = 10

    There was a trend towards greater HD-induced reductions in plasma ADMA concentrations with intra-HD F administration (P = 0.066)

    PMID 18754845 · one of two readings recorded this

  • plasma folic acid change during HD (end-HD vs pre-HD)

    increases, p = 0.01, n = 10

    By contrast, intra-HD F administration was associated with significant increases in F (+298 +/- 283 nmol l(-1), P = 0.010) and a significant reduction of AIx (-4.7 +/- 7.2%, P = 0.013), but no effects on salbutamol-mediated AIx changes (+1.5 +/- 4.4%)

    PMID 18754845 · one of two readings recorded this

  • plasma folic acid change during HD (end-HD vs pre-HD)

    decreases, p = 0.001, n = 10

    Pre-HD F administration did not prevent significant reductions in F during HD (end-HD vs. pre-HD, -865 +/- 465 nmol l(-1), P < 0.001), but no significant changes in AIx (+1.4 +/- 5.7%) or salbutamol-mediated AIx modifications (+0.4 +/- 5.5%) were observed

    PMID 18754845 · one of two readings recorded this

  • salbutamol-mediated augmentation index change during HD

    no effect, n = 10

    By contrast, intra-HD F administration was associated with significant increases in F (+298 +/- 283 nmol l(-1), P = 0.010) and a significant reduction of AIx (-4.7 +/- 7.2%, P = 0.013), but no effects on salbutamol-mediated AIx changes (+1.5 +/- 4.4%)

    PMID 18754845 · one of two readings recorded this

  • salbutamol-mediated augmentation index change during HD

    no effect, n = 10

    Pre-HD F administration did not prevent significant reductions in F during HD (end-HD vs. pre-HD, -865 +/- 465 nmol l(-1), P < 0.001), but no significant changes in AIx (+1.4 +/- 5.7%) or salbutamol-mediated AIx modifications (+0.4 +/- 5.5%) were observed

    PMID 18754845 · one of two readings recorded this

  • advanced adenoma, folic acid vs placebo

    no effect

    these risk ratios were 1.30 (95% CI 0.34, 4.96) and 1.40 (95% CI 0.36, 5.38) respectively

    PMID 18768511 · one of two readings recorded this

  • advanced adenoma, folic acid vs placebo

    no effect

    these risk ratios were 1.30 (95% CI 0.34, 4.96) and 1.40 (95% CI 0.36, 5.38) respectively

    PMID 18768511 · one of two readings recorded this

  • advanced adenoma recurrence, MTHFR 1298CC vs wild type

    no effect, p = 0.71

    and 1.16 (0.58–2.33) for the 1298CC genotype (p for trend = 0.71)

    PMID 18768511 · one of two readings recorded this

  • advanced adenoma recurrence, MTHFR 677TT vs wild type

    no effect, p = 0.28

    The RR’s and 95% CI’s for any advanced lesion were 0.75 (0.36–1.55) for the 677TT genotype (p for trend = 0.28)

    PMID 18768511 · one of two readings recorded this

  • any adenoma, folic acid vs placebo

    no effect

    1.02 (95% CI 0.62, 1.68) for those carrying the MTHFR 1298CC genotype

    PMID 18768511 · one of two readings recorded this

  • any adenoma, folic acid vs placebo

    no effect

    The folate/placebo risk ratio for all adenomas was 0.93 (0.57, 1.53) among those with the MTHFR 677TT genotype

    PMID 18768511 · one of two readings recorded this

  • any adenoma, MTHFR 1298CC vs wild type

    no effect, p = 0.83

    For the 1298CC genotype, these RR’s were 1.15 (95% CI= 0.79, 1.66) and 1.14 (95% CI = 0.79, 1.71) for the folate and placebo groups respectively (p = 0.83)

    PMID 18768511 · one of two readings recorded this

  • any adenoma, MTHFR 1298CC vs wild type

    no effect

    For the 1298CC genotype, these RR’s were 1.15 (95% CI= 0.79, 1.66) and 1.14 (95% CI = 0.79, 1.71) for the folate and placebo groups respectively (p = 0.83)

    PMID 18768511 · one of two readings recorded this

  • any adenoma, MTHFR 677TT vs wild type

    decreases

    The adjusted risk ratios for any adenoma were 1.07 (95% CI = 0.79–1.45) in males but 0.48 in females (95% CI 0.25, 0.90; p for interaction=0.05)

    PMID 18768511 · one of two readings recorded this

  • any adenoma, MTHFR 677TT vs wild type

    no effect, p = 0.05

    The adjusted risk ratios for any adenoma were 1.07 (95% CI = 0.79–1.45) in males but 0.48 in females (95% CI 0.25, 0.90; p for interaction=0.05)

    PMID 18768511 · one of two readings recorded this

  • any adenoma, MTHFR 677TT vs wild type

    no effect, p = 0.85

    For the 677TT genotype, the relative risks for any adenoma were 0.82 (95% CI 0.55, 1.22) and 0.96 (95% CI 0.66, 1.38) among subjects randomized to folate, and placebo respectively (p for interaction =0.85)

    PMID 18768511 · one of two readings recorded this

  • any adenoma, MTHFR 677TT vs wild type

    no effect

    For the 677TT genotype, the relative risks for any adenoma were 0.82 (95% CI 0.55, 1.22) and 0.96 (95% CI 0.66, 1.38) among subjects randomized to folate, and placebo respectively (p for interaction =0.85)

    PMID 18768511 · one of two readings recorded this

  • any recurrent adenoma, MTHFR 1298CC vs wild type

    no effect, p = 0.12

    and 1.14 (0.87–1.50) for the MTHFR 1298CC genotype (p for trend = 0.12)

    PMID 18768511 · one of two readings recorded this

  • any recurrent adenoma, MTHFR 677TT vs wild type

    no effect, p = 0.42

    the adjusted RRs and 95% confidence intervals (CI’s) for any adenoma were 0.89 (0.68–1.16) for the MTHFR 677TT genotype (p for trend over number of variant alleles = 0.42)

    PMID 18768511 · one of two readings recorded this

  • colorectal adenoma recurrence at year-3 surveillance colonoscopy, folic acid versus placebo within MTHFR genotype strata

    no effect, folate/placebo risk ratio for all adenomas 0.93 (0.57, 1.53) among MTHFR 677TT carriers and 1.02 (0.62, 1.68) among 1298CC carriers

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    The folate/placebo risk ratio for all adenomas was 0.93 (0.57, 1.53) among those with the MTHFR 677TT genotype and 1.02 (95% CI 0.62, 1.68) for those carrying the MTHFR 1298CC genotype.

    PMID 18768511 · one of two readings recorded this

  • colorectal adenoma recurrence, folic acid 1 mg/day versus placebo, by MTHFR genotype (677TT, 1298CC)

    no effect, folate/placebo risk ratio for all adenomas 0.93 (0.57, 1.53) in 677TT carriers and 1.02 (0.62, 1.68) in 1298CC carriers

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    The folate/placebo risk ratio for all adenomas was 0.93 (0.57, 1.53) among those with the MTHFR 677TT genotype and 1.02 (95% CI 0.62, 1.68) for those carrying the MTHFR 1298CC genotype.

    PMID 18768511 · one of two readings recorded this

  • any cancer death

    no effect, p = 0.32

    There was no difference in any cancer death (24.6/10000 person-years vs 30.1/10000 person-years; HR, 0.82; 95% CI, 0.56–1.21; P=.32)

    PMID 18984888 · one of two readings recorded this

  • any cancer death

    no effect

    the null results remained for total invasive cancer (148 vs 140 cases; HR, 1.04; 95% CI, 0.83–1.32), breast cancer (59 vs 64 cases; HR, 0.91; 95% CI, 0.64–1.30), and any cancer death (29 vs 36 cases; HR, 0.80; 95% CI, 0.49–1.30)

    PMID 18984888 · one of two readings recorded this

  • any cancer death

    no effect

    After excluding the first 2 years of follow-up as pre-specified, the HRs were 0.94 (95% CI, 0.73–1.20) for total invasive cancer, 0.73 (95% CI, 0.50–1.06) for breast cancer, and 0.92 (95% CI, 0.53–1.60) for any cancer death

    PMID 18984888 · one of two readings recorded this

The whole record — 6,833 rows